Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dimitrios A Pappas

Showing results (21-30 of 76) with videos related to

Pageof 8
Sort By:
Seminars in Arthritis and Rheumatism|November 17, 2024
New onset work disability in rheumatoid arthritis is an underrecognized cardiovascular risk factor: A retrospective cohort study using the CorEvitas registryRobert Spandorfer, Kevin Kane, Dimitrios A Pappas, et al.
Clinical Proteomics|January 20, 2021
Variable blood processing procedures contribute to plasma proteomic variabilityPatrick Halvey, Victor Farutin, Laura Koppes, et al.
Rheumatology International|December 1, 2020
Perceived clinical utility of a test for predicting inadequate response to TNF inhibitor therapies in rheumatoid arthritis: results from a decision impact studyDimitrios A Pappas, Christine Brittle, James E Mossell, et al.
RMD Open|November 8, 2020
Hydroxychloroquine and the risk of respiratory infections among RA patientsJoel M Kremer, George Reed, Dimitrios A Pappas, et al.
Arthritis Research & Therapy|December 21, 2022
The effect of targeted rheumatoid arthritis therapeutics on systemic inflammation and anemia: analysis of data from the CorEvitas RA registryAnthony S Padula, Dimitrios A Pappas, Stefano Fiore, et al.
Rheumatology and Therapy|October 18, 2016
Delays in Initiation of Disease-Modifying Therapy in Rheumatoid Arthritis Patients: Data from a US-Based RegistryDimitrios A Pappas, Jeffrey D Kent, Jeffrey D Greenberg, et al.
Rheumatology and Therapy|October 18, 2016
Characteristics Associated with Biologic Monotherapy Use in Biologic-Naive Patients with Rheumatoid Arthritis in a US Registry PopulationDimitrios A Pappas, George W Reed, Katherine Saunders, et al.
Rheumatology and Therapy|February 25, 2021
Durability of Response to Tocilizumab Therapy in Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis RegistryDimitrios A Pappas, Taylor Blachley, Jennie H Best, et al.
Rheumatology and Therapy|August 16, 2020
Clinical Utility and Cost Savings in Predicting Inadequate Response to Anti-TNF Therapies in Rheumatoid ArthritisMartin J Bergman, Alan J Kivitz, Dimitrios A Pappas, et al.
Seminars in Arthritis and Rheumatism|July 11, 2024
Effect of biologic agents and inflammation on lipid levels and cardiovascular risk in rheumatoid arthritis patientsDimitrios A Pappas, George Reed, Kevin Kane, et al.
Pageof 8

Showing results (21-30 of 76) with videos related to

Sort By:
Pageof 8
Seminars in Arthritis and Rheumatism|November 17, 2024
New onset work disability in rheumatoid arthritis is an underrecognized cardiovascular risk factor: A retrospective cohort study using the CorEvitas registryRobert Spandorfer, Kevin Kane, Dimitrios A Pappas, et al.
Clinical Proteomics|January 20, 2021
Variable blood processing procedures contribute to plasma proteomic variabilityPatrick Halvey, Victor Farutin, Laura Koppes, et al.
Rheumatology International|December 1, 2020
Perceived clinical utility of a test for predicting inadequate response to TNF inhibitor therapies in rheumatoid arthritis: results from a decision impact studyDimitrios A Pappas, Christine Brittle, James E Mossell, et al.
RMD Open|November 8, 2020
Hydroxychloroquine and the risk of respiratory infections among RA patientsJoel M Kremer, George Reed, Dimitrios A Pappas, et al.
Arthritis Research & Therapy|December 21, 2022
The effect of targeted rheumatoid arthritis therapeutics on systemic inflammation and anemia: analysis of data from the CorEvitas RA registryAnthony S Padula, Dimitrios A Pappas, Stefano Fiore, et al.
Rheumatology and Therapy|October 18, 2016
Delays in Initiation of Disease-Modifying Therapy in Rheumatoid Arthritis Patients: Data from a US-Based RegistryDimitrios A Pappas, Jeffrey D Kent, Jeffrey D Greenberg, et al.
Rheumatology and Therapy|October 18, 2016
Characteristics Associated with Biologic Monotherapy Use in Biologic-Naive Patients with Rheumatoid Arthritis in a US Registry PopulationDimitrios A Pappas, George W Reed, Katherine Saunders, et al.
Rheumatology and Therapy|February 25, 2021
Durability of Response to Tocilizumab Therapy in Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis RegistryDimitrios A Pappas, Taylor Blachley, Jennie H Best, et al.
Rheumatology and Therapy|August 16, 2020
Clinical Utility and Cost Savings in Predicting Inadequate Response to Anti-TNF Therapies in Rheumatoid ArthritisMartin J Bergman, Alan J Kivitz, Dimitrios A Pappas, et al.
Seminars in Arthritis and Rheumatism|July 11, 2024
Effect of biologic agents and inflammation on lipid levels and cardiovascular risk in rheumatoid arthritis patientsDimitrios A Pappas, George Reed, Kevin Kane, et al.
Pageof 8